今日13股封单资金超亿元。 涨停战场： 易明医药封单资金居首 据证券时报·数据宝统计，6月9日，从收盘涨停板封单量看，金鹰股份（600232）、易明医药 （002826）、誉衡药业（002437）排名前三，依次有42.56万手、27.39万手、27.22万手；跨境通 （002640）、ST联合（600358）、澳洋健康（002172）、众生药业（002317）等随后，封单量均在20 万手以上。 从连续涨停天数看，ST联合斩获7连板，共创草坪（605099）实现6连板，金时科技（002951）5连板； 易明医药、中嘉博创（000889）4连板；*ST东晶（002199）、*ST生物（000504）3连板。 共创草坪继续发布股票交易风险提示性公告。公司表示，旗下产品以出口为主，2024年公司境外收入占 营业收入的比重为88.62%。国内相关足球体育赛事的举办对公司经营活动和经营业绩不会产生重大影 响。 金时科技6月以来累计涨幅超过60%。公司同样发布公告表示，不存在应披露而未披露的重大事项，请 广大投资者注意风险。公司正处于战略转型期，已从传统烟标印刷业务全面转向新能源储能领域。2024 年实现营业收入3.76亿 ...

证券时报·数据宝统计显示，涨停个股中，主板有80只，北交所1只，创业板10只。以所属行业来看，上 榜个股居前的行业有医药生物、基础化工、轻工制造行业，上榜个股分别有16只、10只、8只。 涨停股中，*ST生物、*ST四环等23只股为ST股。连续涨停天数看，ST联合已连收8个涨停板，连续涨 停板数量最多。从收盘涨停板封单量来看，金鹰股份最受资金追捧，收盘涨停板封单有4255.74万股， 其次是易明医药、誉衡药业等，涨停板封单分别有2739.30万股、2721.58万股。以封单金额计算，易明 医药、众生药业、金鹰股份等涨停板封单资金较多，分别有4.88亿元、3.28亿元、2.98亿元。（数据 宝） 两市涨停股一览 截至收盘，上证指数报收3399.77点，上涨0.43%；深证成指收于10250.14点，上涨0.65%；创业板指上 涨1.07%；科创50指数上涨0.60%。 不含当日上市新股，今日可交易A股中，上涨个股有4121只，占比76.50%，下跌个股有1094只，平盘个 股172只。其中，收盘股价涨停的有91只，跌停股有4只。 | 600520 | 三佳科技 | 30.31 | 8.64 | 236.73 | ...

4月25日公司发布的一季报数据显示，一季度公司共实现营业总收入1.49亿元，同比下降7.41%，实现净 利润0.19亿元，同比下降32.64%。（数据宝） 近日该股表现 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.06.06 | 9.97 | 0.90 | 1606.41 | | 2025.06.05 | 10.00 | 0.30 | 627.58 | | 2025.06.04 | 10.02 | 1.00 | 1388.22 | | 2025.05.26 | 2.53 | 7.37 | -307.58 | | 2025.05.23 | 1.71 | 8.21 | 458.29 | | 2025.05.22 | 0.26 | 3.87 | 560.44 | | 2025.05.21 | -0.09 | 2.77 | 5.80 | | 2025.05.20 | -0.09 | 3.15 | -655.45 | | 2025.05.19 | 0.69 | 3.79 | -45.88 | | 2025.05.16 ...

Group 1 - The chemical pharmaceutical sector experienced a short-term surge, with companies such as Yiming Pharmaceutical (002826) and Anglikang (002940) hitting the daily limit up [1] - Haichen Pharmaceutical (300584) rose over 10%, while other companies like Haisen Pharmaceutical (001367), Erkang Pharmaceutical (300267), Dezhan Health (000813), Fu'an Pharmaceutical (300194), and Sunflower (300111) also saw gains [1]

Core Viewpoint - Yao Jinbo, a pioneer in the internet industry, has become the new actual controller of A-share company Yiming Pharmaceutical (002826.SZ) by investing 6.62 billion yuan, leading to a significant surge in the company's stock price with three consecutive trading limits reached [3][5][6]. Group 1: Investment and Acquisition Details - Yao Jinbo's acquisition of Yiming Pharmaceutical marks his debut in the A-share market, with the stock price rising due to his involvement [3][5]. - The acquisition involved a share transfer agreement where Beijing Fuhai, owned by Yao and his wife, purchased 23% of the company's shares at a price of 15.10 yuan per share, representing a 24% premium over the last closing price before suspension [6][7]. - Yao Jinbo's investment strategy includes a commitment from the previous controller, Gao Fan, to ensure that Yiming Pharmaceutical's revenue remains above 6 billion yuan and net profit above 300 million yuan from 2025 to 2027 [7][8]. Group 2: Company Performance and Market Position - Yiming Pharmaceutical has shown stable but modest performance, with revenues around 700 million yuan and net profits fluctuating around 40 million yuan from 2020 to 2024 [9]. - The company's main product, Miglitol tablets, accounted for 72.72% of its revenue in 2024, while other products, such as the Gua Lou Pi injection, have seen significant declines in revenue [9][10]. - The company has terminated its collaboration with Shanghai Pharmaceuticals regarding the Gua Lou Pi injection, indicating potential shifts in its product strategy [10]. Group 3: Market Speculation and Future Prospects - There is speculation that Yao Jinbo may consider a reverse merger to list 58 Group's assets through Yiming Pharmaceutical, as the latter is viewed as a valuable shell resource [4][18]. - Yao's previous ventures, including 58.com, have faced challenges in the competitive landscape, with various assets underperforming, raising questions about the viability of injecting these assets into Yiming Pharmaceutical [21][23]. - The competitive pressures from companies like BOSS Zhipin, Meituan, and JD.com are significant, and Yao Jinbo must optimize his assets to regain market competitiveness [26][25].

Shareholding Changes - Guotou Chuangye Fund plans to reduce its stake in Huashu Gaoke by up to 2.20%, amounting to a maximum of 9.11 million shares [1] - Biheng Investment intends to reduce its stake in Shentong Technology by up to 3%, totaling a maximum of 12.88 million shares [2] - Guangzhou Chengxin plans to reduce its stake in Jindan Technology by up to 2.93%, which is a maximum of 563.5 thousand shares [3] Regulatory Matters - ST Lutong received an administrative regulatory measure decision from Jiangsu Securities Regulatory Bureau due to internal control deficiencies and failure to disclose significant lawsuits and account freezes [4] - Zhongdian Xinlong confirmed that there are no undisclosed significant matters, despite a stock price fluctuation exceeding 20% over two trading days [5] - Yiming Pharmaceutical stated that there have been no significant changes in its internal and external operating environment, and confirmed the absence of undisclosed significant matters [6]

Group 1 - The company, Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd., experienced abnormal stock trading fluctuations on June 5 and June 6, 2025, as per the relevant regulations [1] - The board of directors confirmed that there are no undisclosed significant matters affecting the company's stock price, apart from the disclosed share transfer agreement with Beijing Fuhai, which involves the acquisition of 43,855,883 shares from the controlling shareholder Gao Fan [1][2] - The company has disclosed the necessary documents regarding the change of control, including a brief and detailed report on equity changes, and has confirmed that there are no other undisclosed matters that could impact the stock price [2] Group 2 - The company will continue to comply with legal and regulatory requirements for information disclosure and will ensure timely updates regarding any significant changes [2] - The completion of the equity change is subject to compliance confirmation from the Shenzhen Stock Exchange and other necessary approvals, indicating potential uncertainties in the implementation of the transaction [2]

西藏易明西雅医药科技股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：002826 证券简称：易明医药 公告编号：2025-040 一、 股票交易异常波动的情况介绍 西藏易明西雅医药科技股份有限公司（以下简称"公司"或"本公司"） 股票（证券代码：002826，证券简称：易明医药）于2025年6月5日、2025年6月 6日连续两个交易日内日收盘价涨幅偏离值累计达到20％以上，根据深圳证券交 易所的相关规定，属于股票交易异常波动的情况。 二、对重要问题的关注、核实情况的说明 针对公司股票异常波动，公司董事会对公司、控股股东及实际控制人就相 关事项进行了核实，现就有关情况说明如下： 5、经核查，公司控股股东及实际控制人在本公司股票交易异常波动期间未 买卖本公司股票； 6、公司不存在违反公平信息披露规定的情形。 三、是否存在应披露而未披露信息的说明 本公司董事会确认，除前述事项（指第二部分涉及的披露事项）外，本公 司目前没有任何根据《深圳证券交易所股票上市规则》有关规定应予以披露而 未披露的事项或与该事项有关的筹划、商谈、 ...

Group 1 - Yiming Pharmaceutical (002826) closed at 16.21 yuan on June 6, 2025, a 33.09% increase from the previous week's 12.18 yuan, reaching a near one-year high [1] - The company's total market capitalization is currently 3.091 billion yuan, ranking 127th out of 150 in the chemical pharmaceutical sector and 4141st out of 5148 in the A-share market [1] - The stock was listed on the "Dragon and Tiger List" for the first time in five trading days due to a cumulative price deviation of 20% over three consecutive trading days [1][3] Group 2 - The company announced that its controlling shareholder, Gao Fan, plans to transfer 23% of his shares (43,855,883 shares) to Beijing Fuhai at a price of 15.10 yuan per share, totaling approximately 662.22 million yuan [1] - Following this equity change, the controlling shareholder will shift from Gao Fan to Beijing Fuhai, with the actual controller changing to Yao Jinbo [1][3] - Yiming Pharmaceutical's wholly-owned subsidiary, Sichuan Weiao Pharmaceutical Co., Ltd., received a government subsidy of 4.853 million yuan, which is expected to increase the company's total profit for 2025 by the same amount [2][3]

Group 1 - Yiming Pharmaceutical (002826.SZ) has experienced a significant stock price increase, reaching a new high of 16.21 CNY per share, with a market capitalization of 3.09 billion CNY following the announcement of a share transfer agreement [1] - The controlling shareholder, Gao Fan, is transferring 23% of the company's shares to Beijing Fuhai at a price of 15.1 CNY per share, totaling 662 million CNY [1] - After the acquisition, the controlling shareholder will change from Gao Fan to Yao Jinbo, who is also the founder of 58.com [1] Group 2 - Yiming Pharmaceutical has been facing declining performance, with revenues of 857 million CNY in 2022, 667 million CNY in 2023, and projected 652 million CNY in 2024, alongside net profits of 46 million CNY, 16 million CNY, and 47 million CNY respectively [2][3] - The company's revenue is heavily reliant on a single product, Miglitol tablets, which accounted for 72.72% of total revenue in 2024, indicating a rising dependency on this product [5] Group 3 - The share transfer agreement includes performance commitments, where Gao Fan guarantees that the net profit attributable to the parent company will not be less than 30 million CNY for the years 2025, 2026, and 2027 [4] - The new management structure will involve a significant change, with the incoming shareholder nominating three non-independent directors and three independent directors [5] Group 4 - Gao Fan's exit from the company has been anticipated, as he has gradually reduced his involvement since 2021 and has made multiple share sell-off announcements [7][8] - Yiming Pharmaceutical's attempts to strengthen its market position through fundraising and acquisitions have faced challenges, including a failed private placement plan and a withdrawal from an investment in a foreign company [8] Group 5 - The acquisition by Yao Jinbo, a prominent figure in the internet industry, raises questions about the potential growth and strategic direction for Yiming Pharmaceutical [10][11] - Yao Jinbo has a history of capital operations and has established significant investment funds focusing on emerging sectors like renewable energy and artificial intelligence [11]